GlassScriptPhysician profile
Ashley Lamonica
NPI 1316777279
$1,344.92
in general payments reported to CMS, 2019-2025
18 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $63.34 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.02 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $184.34 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $92.84 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $90.17 | 2025 | Shingrix, Trelegy Ellipta |
| Alk-Abello, INC | $79.57 | 2025 | Neffy, Odactra, Grastek |
| Lilly USA, LLC | $77.52 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $72.08 | 2025 | |
| Optinose US, INC. | $65.37 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.73 | 2025 | Xifaxan |
| Amgen INC. | $41.73 | 2024-2025 | Otezla, Repatha, Repatha |
| Daiichi Sankyo INC. | $34.52 | 2024-2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $27.78 | 2025 | |
| Phathom Pharmaceuticals, INC. | $24.05 | 2025 | Voquezna |
| Seqirus USA INC | $21.87 | 2025 | Fluad, Flucelvax |
| Ani Pharmaceuticals, INC. | $17.71 | 2025 | Purified Cortrophin Gel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $16.36 | 2025 | Jatenzo |
| Cumberland Pharmaceuticals, INC. | $15.58 | 2025 | Kristalose |
| Exact Sciences Corporation | $14.68 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lamonica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.